<DOC>
	<DOCNO>NCT01076478</DOCNO>
	<brief_summary>To describe difference subjective , objective electrophysiologic parameter diabetic polyneuropathies baseline , four ( 4 ) week , eight ( 8 ) week , twelve ( 12 ) week Cilostazol therapy .</brief_summary>
	<brief_title>Asian Study Cilostazol Effectivity Neuropathies Diabetes Mellitus Type 2-A Pilot Study Philippines</brief_title>
	<detailed_description />
	<mesh_term>Polyneuropathies</mesh_term>
	<mesh_term>Cilostazol</mesh_term>
	<criteria>1 . Signed write informed consent 2 . Male Female age 18 70 year old . To able eliminate Type I Diabetes Mellitus among young subject , recruit patient stable oral hypoglycemic agent . 3 . Established diagnosis diabetes mellitus type 2 ( National Diabetes Data Group ) currently good control diabetic state . 4 . Presence predominantly distal symmetrical sensory polyneuropathy lower limb assess NSS , NIS NCS . 1 . Current use potentially neuropathic agent ( Isoniazid , Phenytoin , Dapsone , Metronidazole , Vinca Alkaloids , etc . ) within past 1 month ; 2 . Presence severe metabolic disease ( renal failure , hepatic failure , etc . ) , alcoholism malignancy ; 3 . Presence hemorrhagic tendency ; 4 . Patients diagnose Type 1 Diabetes Mellitus ; 5 . Pregnant lactating patient , include plan pregnancy within study period . 6 . Concomitant intake agent currently use treat neuropathic pain like gabapentin , carbamazepine/ oxcarbazepine , antidepressant ( tricyclic antidepressant SSRIs ) topical capsaicin . 7 . Concomitant intake antiplatelet agent , rheologic agent anticoagulant . 8 . Have receive Cilostazol therapy within past three ( 3 ) month</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>February 2010</verification_date>
	<keyword>Symmetric Diabetic Polyneuropathy</keyword>
</DOC>